A small, short-term, double-blind, Swedish study involving 60 healthy postmenopausal women finds that 60 mg isoflavones daily can reduce hot flashes and night sweats by about half without any negative effects on the endometrium, breasts, or lipid levels.
A small, short-term, double-blind, Swedish study involving 60 healthy postmenopausal women finds that 60 mg isoflavones daily can reduce hot flashes and night sweats by about half without any negative effects on the endometrium, breasts, or lipid levels.
Researchers gave participants a soybean-based fruit drink containing 60 mg isoflavones or placebo daily for 3 months. They found that in the women receiving the isoflavones, hot flashes and night sweats were reduced by 57% and 43%, respectively, without changes in levels of circulating estradiol or follicle-stimulating hormone and without affecting expression levels of steroid receptors; estrogen receptors α, β, and βcx; progesterone receptors A and B; or the proliferation marker Ki67. Furthermore, the authors of the study observed no side effects on body weight, lipoprotein profiles, or endometrial thickness as measured by ultrasound.
The researchers concluded that while the findings are encouraging, the question of whether isoflavones can substitute for estrogen replacement requires further investigation.
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Genetics associated with reproductive traits and uterine leiomyomata
April 17th 2024Investigating genetic correlations and shared loci sheds light on potential causal relationships between reproductive traits and uterine leiomyomata, offering insights into their complex interplay and urging further mechanistic exploration.
Read More
Study finds reduced CIN3+ risk from early HPV vaccination
April 16th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
Read More